Themis Medicare
NSE: THEMISMED · Pharmaceuticals
Snapshot
Unlock Themis Medicare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Themis Medicare Limited is a pharmaceutical company that manufactures and markets active pharmaceutical ingredients and finished formulations. Its product portfolio spans diverse therapeutic areas including oncology, cardiology, anti-infectives, and pain management.
Business Model
The company generates revenue through the production and sale of pharmaceutical products across domestic and international markets. It operates as a vertically integrated player, leveraging its manufacturing capabilities to serve both domestic healthcare needs and global export requirements.
Growth Outlook
Growth is driven by the expansion of its therapeutic portfolio and the strengthening of its presence in both domestic and international pharmaceutical markets. The company continues to focus on its core competencies in API and formulation manufacturing to capture market share.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from domestic and international health authorities, where non-compliance could lead to product recalls or manufacturing bans.
- Price Controls. The Indian pharmaceutical sector is subject to government-mandated price caps on essential medicines, which may impact profit margins.
- Competitive Intensity. The pharmaceutical industry is highly fragmented and competitive, requiring constant investment in R&D to maintain market positioning.
- Supply Chain Volatility. Dependence on raw material imports for API manufacturing exposes the company to global supply chain disruptions and currency fluctuations.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Themis Medicare and 5,000+ companies — free.
Key Metrics
REVENUE
₹342 Cr
TTM · consolidated
NET PROFIT
₹1 Cr
TTM · consolidated
EPS
₹0.13
TTM · consolidated
RETURN ON EQUITY
0.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
-0.3%
TTM · consolidated
P/E
864.8x
Q4 FY26 · consolidated
EV/EBITDA
116.1x
Q4 FY26 · consolidated
EBITDA MARGIN
2.8%
TTM · consolidated
NET PROFIT MARGIN
11.6%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Themis MedicareTHEMISMED | 663 | 864.77 | 116.11 | -15.6% | 2.8% | 0.3% | -0.3% | -9.9% |
Anuh PharmaANUHPHR | 713 | 16.26 | 12.03 | 16.7% | 8.6% | 12.3% | 16.3% | -21.7% |
Sigachi Indust.SIGACHI | 710 | -11.46 | 16.97 | -2.1% | 13.0% | -14.3% | -11.6% | -40.8% |
Bharat Parenter.BPLPHARMA | 689 | 33.00 | 14.73 | 9.4% | 21.2% | 8.3% | 9.0% | -16.7% |
Shree Ganesh RemSGRL | 624 | 47.05 | 22.40 | — | 34.8% | 11.9% | 15.9% | +7.6% |
Anlon HealthcareAHCL | 605 | 1.97 | 13.92 | — | 26.3% | 13.3% | 20.9% | — |
As of Q4 FY26
Financials
Themis Medicare
NSE: THEMISMED · Pharmaceuticals
Snapshot
Unlock Themis Medicare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Themis Medicare Limited is a pharmaceutical company that manufactures and markets active pharmaceutical ingredients and finished formulations. Its product portfolio spans diverse therapeutic areas including oncology, cardiology, anti-infectives, and pain management.
Business Model
The company generates revenue through the production and sale of pharmaceutical products across domestic and international markets. It operates as a vertically integrated player, leveraging its manufacturing capabilities to serve both domestic healthcare needs and global export requirements.
Growth Outlook
Growth is driven by the expansion of its therapeutic portfolio and the strengthening of its presence in both domestic and international pharmaceutical markets. The company continues to focus on its core competencies in API and formulation manufacturing to capture market share.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from domestic and international health authorities, where non-compliance could lead to product recalls or manufacturing bans.
- Price Controls. The Indian pharmaceutical sector is subject to government-mandated price caps on essential medicines, which may impact profit margins.
- Competitive Intensity. The pharmaceutical industry is highly fragmented and competitive, requiring constant investment in R&D to maintain market positioning.
- Supply Chain Volatility. Dependence on raw material imports for API manufacturing exposes the company to global supply chain disruptions and currency fluctuations.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Themis Medicare and 5,000+ companies — free.
Key Metrics
REVENUE
₹342 Cr
TTM · consolidated
NET PROFIT
₹1 Cr
TTM · consolidated
EPS
₹0.13
TTM · consolidated
RETURN ON EQUITY
0.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
-0.3%
TTM · consolidated
P/E
864.8x
Q4 FY26 · consolidated
EV/EBITDA
116.1x
Q4 FY26 · consolidated
EBITDA MARGIN
2.8%
TTM · consolidated
NET PROFIT MARGIN
11.6%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26